Avanos Medical, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Avanos Medical (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026 at approximately 2:15 p.m. PST. A live webcast will be available on the company Investors website and the presentation will be archived there for later viewing.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AVNS gained 4.79%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: OFIX up 0.38%, SIBN up 2.34%, while BVS and CTKB are down 0.78% and 0.9%, respectively, suggesting AVNS’s slight decline is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Negative | -5.7% | Q3 net loss and weaker profitability despite modest sales growth and guidance update. |
| Oct 27 | Earnings call notice | Neutral | -0.8% | Announcement of webcast details for upcoming Q3 2025 earnings discussion. |
| Oct 23 | Business divestiture | Neutral | -0.3% | Agreement to sell US Game Ready orthopedic rental business with supply agreement. |
| Sep 15 | Nexus acquisition | Positive | +0.4% | Acquisition of Nexus Medical to strengthen critical care nutrition and medication delivery. |
| Aug 05 | Management changes | Neutral | -12.1% | CFO appointment and CEO joining board accompanied by a sharp share price drop. |
Recent news has often coincided with downside moves, especially around earnings and restructuring, with only the Nexus Medical acquisition showing a modest positive reaction.
Over the last six months, Avanos reported Q3 2025 results on Nov 5, 2025 with higher sales but a net loss, and the stock fell 5.66%. A prior call announcement on Oct 27, 2025 and two portfolio transactions (including the Nexus Medical acquisition and a Game Ready® business divestiture) produced muted price changes, with only a 0.41% uptick on the Nexus deal. Management changes on Aug 5, 2025 coincided with a 12.09% drop. Today’s conference appearance fits a pattern of active strategic communication amid restructuring.
Market Pulse Summary
This announcement highlights Avanos’s participation in a major healthcare investor conference, with management presenting on Jan 13, 2026. In recent months, the company has reported Q3 2025 losses, executed acquisitions and divestitures, and undertaken restructuring with executive changes. Investors may watch for any updated commentary on these initiatives and financial trends during the presentation, as well as how management frames progress on cost savings and portfolio strategy.
AI-generated analysis. Not financial advice.
A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.
About Avanos Medical, Inc.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302655855.html
SOURCE Avanos Medical
FAQ
When will Avanos Medical (AVNS) present at the J.P. Morgan Healthcare Conference?
Who from Avanos Medical (AVNS) is presenting at the Jan. 13, 2026 conference?
How can investors watch Avanos Medical (AVNS) presentation at the J.P. Morgan conference?
Will the Avanos Medical (AVNS) J.P. Morgan presentation be available after the event?
